サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1513334

末梢動脈疾患市場：製品タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024年～2035年

Peripheral Artery Disease Market By Product Type (Devices, Drugs), By End User (Hospitals, Specialty Clinics): Global Opportunity Analysis and Industry Forecast, 2024-2035

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
末梢動脈疾患市場：製品タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024年～2035年
出版日: 2024年04月01日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要
世界の末梢動脈疾患市場は、2023年には45億米ドルと評価され、2024年から2035年までのCAGRは7.7％で成長し、2035年には108億米ドルに達すると推定されています。末梢動脈疾患は、四肢（通常は脚）に血液を供給する動脈の狭窄や閉塞を特徴とする疾患です。これは動脈に脂肪沈着物（プラーク）が蓄積するために起こるもので、アテローム性動脈硬化症として知られるプロセスです。その結果、脚への血流が制限され、特に運動時に脚の痛み、けいれん、しびれ、脱力感などの症状が現れます。末梢動脈疾患の治療は、症状の管理、合併症の予防、血流の改善を目的としています。閉塞した動脈を開いて血流を回復させるために処置や手術が必要になることがあります。これには血管形成術（バルーンで動脈を広げる）やステント留置術（動脈を開いたままにする）が含まれます。
Peripheral Artery Disease Market-IMG1
末梢動脈疾患市場の成長は、高齢者人口の増加と低侵襲手術技術の進歩に起因しています。世界保健機関（WHO）の2022年報告書によると、老人人口（60歳以上）は世界人口の約22％を占めると推定されています。高齢になるにつれて、特に糖尿病、高血圧、喫煙歴など他の心血管危険因子を持つ人々の間で、末梢動脈疾患を発症するリスクが上昇します。多くの国で人口動態が高齢者層へとシフトしており、末梢動脈疾患の発生率と有病率はエスカレートすると予想されます。National Library of Medicineによる2023年の報告によると、末梢動脈疾患の発生率は70歳以上で20％にまで増加すると報告されています。このように、老年人口は末梢動脈疾患の罹患率が高いため、老年人口の増加は末梢動脈疾患市場の成長にプラスの影響を与えると予想されます。さらに、低侵襲手技の技術的進歩は末梢動脈疾患市場の主要な促進要因として浮上しており、診断と治療の状況を一変させています。血管形成術、ステント留置術、アテレクトミーなどの低侵襲技術は、従来の開腹手術に代わるより安全で効果的な方法を提供することで、末梢動脈疾患の管理に革命をもたらしました。これらの手技は、従来の外科的アプローチと比較して、切開創が小さく、周辺組織への外傷が少なく、回復時間が短く、合併症のリスクが低いです。例えば、大手医療機器メーカーであるMedtronic Plcは、完全なSE血管ステントシステムを提供しています。完全なSE血管ステントシステムは、表在性大腿動脈と近位膝窩動脈の末梢動脈疾患を治療するように設計されています。このステントは詰まった動脈を開き、血管形成術後に動脈を支持することによって血流を回復させるように設計されています。末梢動脈疾患市場は、製品タイプ、エンドユーザー、地域によって区分されます。製品タイプ別では、市場は薬剤とデバイスに二分されます。エンドユーザー別では、市場は病院、専門クリニック、外来手術センターに分けられます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋地域）、南米地域（ブラジル、サウジアラビア、アフリカ、その他南米地域）で分析されます。末梢動脈疾患市場で事業を展開する主な主要企業は、Philips N.V.、Braun Melsungen AG、Medtronic、Bayer AG、Boston Scientific Corporation、Becton Dickinson and Company、Terumo Medical Corporation、Biotronik、Cardinal Health、Abbottです。主要企業は、末梢動脈疾患市場の製品ポートフォリオを改善するための主要な開発戦略として製品承認を採用しています利害関係者にとっての主な利点
  • 当レポートは、2023年から2035年までの末梢動脈疾患市場分析の市場セグメント、現在の動向、推定・動向、力学の定量的分析を提供し、一般的な末梢動脈疾患市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
  • 末梢動脈疾患市場のセグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
  • 本レポートは、地域および世界の末梢動脈疾患市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含んでいます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 末梢動脈疾患市場：製品タイプ別

  • 概要
  • デバイス
    • デバイス末梢動脈疾患市場：デバイスタイプ別
  • 医薬品
    • 薬剤タイプ別末梢動脈疾患市場

第5章 末梢動脈疾患市場：エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック

第6章 末梢動脈疾患市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • オーストラリア
    • インド
    • 韓国
    • その他
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2023年

第8章 企業プロファイル

  • Koninklijke Philips N.V.
  • B. Braun Melsungen AG
  • Medtronic
  • Bayer AG
  • Boston Scientific Corporation
  • Becton Dickinson and Company
  • Terumo Medical Corporation
  • Biotronik SE & Co. KG
  • Cardinal Health
  • Abbott Laboratories
図表

LIST OF TABLES

  • TABLE 01. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 02. PERIPHERAL ARTERY DISEASE MARKET FOR DEVICES, BY REGION, 2023-2035 ($MILLION)
  • TABLE 03. GLOBAL DEVICES PERIPHERAL ARTERY DISEASE MARKET, BY DEVICES TYPE, 2023-2035 ($MILLION)
  • TABLE 04. PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 05. GLOBAL DRUGS PERIPHERAL ARTERY DISEASE MARKET, BY DRUG TYPE, 2023-2035 ($MILLION)
  • TABLE 06. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 07. PERIPHERAL ARTERY DISEASE MARKET FOR HOSPITALS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 08. PERIPHERAL ARTERY DISEASE MARKET FOR SPECIALTY CLINICS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 09. PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2023-2035 ($MILLION)
  • TABLE 10. NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 11. NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 12. NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 13. U.S. PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 14. U.S. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 15. CANADA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 16. CANADA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 17. MEXICO PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 18. MEXICO PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 19. EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 20. EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 21. EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 22. GERMANY PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 23. GERMANY PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 24. FRANCE PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 25. FRANCE PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 26. UK PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 27. UK PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 28. ITALY PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 29. ITALY PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 30. SPAIN PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 31. SPAIN PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 32. REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 33. REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 34. ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 35. ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 36. ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 37. JAPAN PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 38. JAPAN PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 39. CHINA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 40. CHINA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 41. AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 42. AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 43. INDIA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 44. INDIA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 45. SOUTH KOREA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 46. SOUTH KOREA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 47. REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 49. LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 50. LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 51. LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 52. BRAZIL PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 53. BRAZIL PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 54. SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 55. SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 56. SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 57. SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 58. REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 59. REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 60. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 61. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 62. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
  • TABLE 63. KONINKLIJKE PHILIPS N.V.: SERVICE SEGMENTS
  • TABLE 64. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 65. KONINKLIJKE PHILIPS N.V.: KEY STRATEGIES
  • TABLE 66. B. BRAUN MELSUNGEN AG: KEY EXECUTIVES
  • TABLE 67. B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • TABLE 68. B. BRAUN MELSUNGEN AG: PRODUCT SEGMENTS
  • TABLE 69. B. BRAUN MELSUNGEN AG: SERVICE SEGMENTS
  • TABLE 70. B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
  • TABLE 71. B. BRAUN MELSUNGEN AG: KEY STRATEGIES
  • TABLE 72. MEDTRONIC: KEY EXECUTIVES
  • TABLE 73. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 74. MEDTRONIC: PRODUCT SEGMENTS
  • TABLE 75. MEDTRONIC: SERVICE SEGMENTS
  • TABLE 76. MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 77. MEDTRONIC: KEY STRATEGIES
  • TABLE 78. BAYER AG: KEY EXECUTIVES
  • TABLE 79. BAYER AG: COMPANY SNAPSHOT
  • TABLE 80. BAYER AG: PRODUCT SEGMENTS
  • TABLE 81. BAYER AG: SERVICE SEGMENTS
  • TABLE 82. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 83. BAYER AG: KEY STRATEGIES
  • TABLE 84. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 85. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 86. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 87. BOSTON SCIENTIFIC CORPORATION: SERVICE SEGMENTS
  • TABLE 88. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 89. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIES
  • TABLE 90. BECTON DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 91. BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 92. BECTON DICKINSON AND COMPANY: PRODUCT SEGMENTS
  • TABLE 93. BECTON DICKINSON AND COMPANY: SERVICE SEGMENTS
  • TABLE 94. BECTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. BECTON DICKINSON AND COMPANY: KEY STRATEGIES
  • TABLE 96. TERUMO MEDICAL CORPORATION: KEY EXECUTIVES
  • TABLE 97. TERUMO MEDICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 98. TERUMO MEDICAL CORPORATION: PRODUCT SEGMENTS
  • TABLE 99. TERUMO MEDICAL CORPORATION: SERVICE SEGMENTS
  • TABLE 100. TERUMO MEDICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 101. TERUMO MEDICAL CORPORATION: KEY STRATEGIES
  • TABLE 102. BIOTRONIK SE & CO. KG: KEY EXECUTIVES
  • TABLE 103. BIOTRONIK SE & CO. KG: COMPANY SNAPSHOT
  • TABLE 104. BIOTRONIK SE & CO. KG: PRODUCT SEGMENTS
  • TABLE 105. BIOTRONIK SE & CO. KG: SERVICE SEGMENTS
  • TABLE 106. BIOTRONIK SE & CO. KG: PRODUCT PORTFOLIO
  • TABLE 107. BIOTRONIK SE & CO. KG: KEY STRATEGIES
  • TABLE 108. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 109. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 110. CARDINAL HEALTH: PRODUCT SEGMENTS
  • TABLE 111. CARDINAL HEALTH: SERVICE SEGMENTS
  • TABLE 112. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 113. CARDINAL HEALTH: KEY STRATEGIES
  • TABLE 114. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 115. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 116. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 117. ABBOTT LABORATORIES: SERVICE SEGMENTS
  • TABLE 118. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 119. ABBOTT LABORATORIES: KEY STRATEGIES

LIST OF FIGURES

  • FIGURE 01. PERIPHERAL ARTERY DISEASE MARKET, 2023-2035
  • FIGURE 02. SEGMENTATION OF PERIPHERAL ARTERY DISEASE MARKET,2023-2035
  • FIGURE 03. TOP IMPACTING FACTORS IN PERIPHERAL ARTERY DISEASE MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN PERIPHERAL ARTERY DISEASE MARKET (2024-2035)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL PERIPHERAL ARTERY DISEASE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023 AND 2035(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR DEVICES, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 14. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023 AND 2035(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR SPECIALTY CLINICS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 17. PERIPHERAL ARTERY DISEASE MARKET BY REGION, 2023 AND 2035(%)
  • FIGURE 18. U.S. PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 19. CANADA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 20. MEXICO PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 21. GERMANY PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 22. FRANCE PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 23. UK PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 24. ITALY PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 25. SPAIN PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 26. REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 27. JAPAN PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 28. CHINA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 29. AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 30. INDIA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 31. SOUTH KOREA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 32. REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 33. BRAZIL PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 34. SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 35. SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 36. REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: PERIPHERAL ARTERY DISEASE MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2023
目次
Product Code: A03968
The global peripheral artery disease market was valued at $4.5 billion in 2023, and is estimated to reach $10.8 billion by 2035, growing at a CAGR of 7.7% from 2024 to 2035. Peripheral artery disease is a condition characterized by the narrowing or blockage of arteries that supply blood to the limbs, typically the legs. This occurs due to the buildup of fatty deposits (plaques) in the arteries, a process known as atherosclerosis. As a result, blood flow to the legs is restricted, leading to symptoms such as leg pain, cramping, numbness, and weakness, particularly during physical activity. Treatment for peripheral artery disease aims to manage symptoms, prevent complications, and improve blood flow. Procedures or surgeries may be required to open blocked arteries and restore blood flow. These can include angioplasty (where a balloon is used to widen the artery) or stent placement (to keep the artery open).
Peripheral Artery Disease Market - IMG1
The peripheral artery disease market growth is attributed to rise in geriatric population, and technological advancements in minimally invasive surgical technology. According to 2022 report by World Health Organization, it was estimated that, the geriatric population (aged 60 and above) is expected to contribute about 22% of global population. As people age, the risk of developing peripheral artery disease rises, especially among those with other cardiovascular risk factors such as diabetes, hypertension, and smoking history. With populations in many countries experiencing a demographic shift towards older age brackets, the incidence and prevalence of peripheral artery disease are expected to escalate. According to the 2023 report by the National Library of Medicine, it was reported that incidence of peripheral artery disease increases to as high as 20% in people over the age of 70. Thus, as the geriatric population has a higher incidence rate of peripheral artery disease, the rise in geriatric population is expected to positively impact the growth of peripheral artery disease market.In addition, technological advancements in minimally invasive procedures have emerged as a major driver for the peripheral artery disease market, transforming the landscape of diagnosis and treatment. Minimally invasive techniques, such as angioplasty, stenting, and atherectomy, have revolutionized the management of peripheral artery disease by offering safer and more effective alternatives to traditional open surgeries. These procedures involve smaller incisions, reduced trauma to surrounding tissues, shorter recovery times, and lower risk of complications compared to conventional surgical approaches. For instance, Medtronic Plc, a leading medical devices company, provides a complete SE vascular stent system. The complete SE vascular stent system is designed to treat peripheral arterial disease in the superficial femoral arteries and proximal popliteal arteries. The stent is designed to open clogged arteries and restore blood flow by providing support to the artery after angioplasty. Thus, the advantages of minimally invasive procedures such as shorter hospital stays and reduced physical trauma (caused in traditional open surgery) are expected to drive the growth of the market.The peripheral artery disease market is segmented by product type, end user, and region. By product type the market is bifurcated into drugs and devices. By end user, the market is divided into hospitals, specialized clinics and ambulatory surgeries centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the peripheral artery disease market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health, Abbott. Key players have adopted product approval as a key developmental strategy to improve the product portfolio of the peripheral artery disease marketKey Benefits For Stakeholders
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peripheral artery disease market analysis from 2023 to 2035 to identify the prevailing peripheral artery disease market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the peripheral artery disease market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global peripheral artery disease market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Devices
    • Devices type
    • Peripheral Angioplasty Balloons
    • Peripheral Stents
    • Peripheral Catheters
    • Inferior Vena Cava Filters
    • Plaque Modification Devices
    • Hemodynamic Flow Alteration Devices
    • Peripheral Accessories
  • Drugs
    • Drug Type
    • Antiplatelet medicines
    • Statins
    • Anti Hypertensive Medication
    • Others

By End User

  • Specialty Clinics
  • Hospitals

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Koninklijke Philips N.V.
    • B. Braun Melsungen AG
    • Medtronic
    • Bayer AG
    • Boston Scientific Corporation
    • Becton Dickinson and Company
    • Terum

Medical Corporation

    • Biotronik SE & Co. KG
    • Cardinal Health
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Devices
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Devices Peripheral Artery Disease Market by Devices type
  • 4.3. Drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Drugs Peripheral Artery Disease Market by Drug Type

CHAPTER 5: PERIPHERAL ARTERY DISEASE MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Specialty Clinics
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PERIPHERAL ARTERY DISEASE MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Product Type
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Product Type
      • 6.2.4.1.2. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Product Type
      • 6.2.4.2.2. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Product Type
      • 6.2.4.3.2. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Product Type
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Product Type
      • 6.3.4.1.2. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Product Type
      • 6.3.4.2.2. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Product Type
      • 6.3.4.3.2. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Product Type
      • 6.3.4.4.2. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Product Type
      • 6.3.4.5.2. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Product Type
      • 6.3.4.6.2. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Product Type
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Product Type
      • 6.4.4.1.2. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Product Type
      • 6.4.4.2.2. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Market size and forecast, by Product Type
      • 6.4.4.3.2. Market size and forecast, by End User
      • 6.4.4.4. India
      • 6.4.4.4.1. Market size and forecast, by Product Type
      • 6.4.4.4.2. Market size and forecast, by End User
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Product Type
      • 6.4.4.5.2. Market size and forecast, by End User
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Product Type
      • 6.4.4.6.2. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Product Type
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Product Type
      • 6.5.4.1.2. Market size and forecast, by End User
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Product Type
      • 6.5.4.2.2. Market size and forecast, by End User
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Product Type
      • 6.5.4.3.2. Market size and forecast, by End User
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Product Type
      • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Koninklijke Philips N.V.
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. B. Braun Melsungen AG
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Medtronic
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Bayer AG
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Boston Scientific Corporation
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Becton Dickinson and Company
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Terumo Medical Corporation
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Biotronik SE & Co. KG
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. Cardinal Health
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. Abbott Laboratories
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments